Patient and treatment characteristics
| Measure . | All patients, n = 21, (%) . |
|---|---|
| Gender | |
| Male | 17 (81) |
| Female | 4 (19) |
| Age | |
| Mean (SD) | 37.9 (16.2) |
| Median (range) | 29.9 (16.9-65.6) |
| Race/ethnicity | |
| White | 13 (62) |
| Hispanic | 8 (38) |
| High-risk cytogenetic/molecular risk at diagnosis | 18 (90) |
| Ph+ | 2 |
| Ph-like | 8 |
| KMT2A | 4 |
| Complex* | 2 |
| Hypodiploid | 2 |
| Days from HCT to blinatumomab start | |
| Median (range) | 78.0 (44.0-105.0) |
| MRD prior to blinatumomab treatment | |
| Detected | 2 (10) |
| Not detected | 19 (90) |
| Number of cycles | |
| 1 | 21 |
| 2 | 13 |
| 3 | 12 |
| 4 | 12 |
| Measure . | All patients, n = 21, (%) . |
|---|---|
| Gender | |
| Male | 17 (81) |
| Female | 4 (19) |
| Age | |
| Mean (SD) | 37.9 (16.2) |
| Median (range) | 29.9 (16.9-65.6) |
| Race/ethnicity | |
| White | 13 (62) |
| Hispanic | 8 (38) |
| High-risk cytogenetic/molecular risk at diagnosis | 18 (90) |
| Ph+ | 2 |
| Ph-like | 8 |
| KMT2A | 4 |
| Complex* | 2 |
| Hypodiploid | 2 |
| Days from HCT to blinatumomab start | |
| Median (range) | 78.0 (44.0-105.0) |
| MRD prior to blinatumomab treatment | |
| Detected | 2 (10) |
| Not detected | 19 (90) |
| Number of cycles | |
| 1 | 21 |
| 2 | 13 |
| 3 | 12 |
| 4 | 12 |
Complex karyotype defined as 5 or more cytogenetic abnormalities.